Why Axsome Therapeutics, Inc. (AXSM) stock moved
Axsome Therapeutics, Inc. (AXSM) shares climbed 5.2% to $140.94 as of November 10, 2026, a significant gain from the prior close of $133.96. BestStocks flagged the session as a major change for AXSM. Below, we break down what changed for AXSM, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
AXSM climbed 5.2% to $140.94
Axsome Therapeutics rose 6.30% to $142.40 following a presentation by company leadership (COO Mark Jacobson and CFO Nick Pizzie) at the 3rd Annual Guggenheim Healthcare Innovation Conference on November 9, 2026, per SeekingAlpha. The gain reflects investor interest in management commentary, though specific details of the presentation were not disclosed in available sources. Earnings release scheduled for February 22, 2027 (consensus EPS estimate: −$0.06); monitor for any press releases or filings disclosing material details from today's Guggenheim presentation.
What it means for Axsome Therapeutics, Inc. investors
For Axsome Therapeutics, Inc. investors, the balance of recent signals points to a bullish shift. On the constructive side: Material positive event; Strong 5.2% price move. Weighing against that: Axsome Therapeutics reported Q3 2026 earnings today, beating revenue estimates but posting a net loss, according to Zacks and the company's earnings release via Globe Newswire; Axsome Therapeutics, Inc. moved -3.74% intraday from $203.10 to $195.50. Wall Street's consensus price target sits at $279.25, implying +98.1% upside from $140.94. BestStocks rates the overall signal quality low (59/100). With earnings roughly 104 days out, the next report is the most likely near-term test of the move.
AXSM price reaction
AXSM last traded at $140.94, up $6.98 (+5.21%) from the previous close of $133.96. The session traded on 1.1× average volume (normal), so participation was unremarkable. Over the past month the stock has ranged between $129.80 and $166.00, and it currently sits about 31% of the way up that band.
Bullish and bearish analyst opinions on Axsome Therapeutics, Inc. (AXSM)
The consensus analyst price target on Axsome Therapeutics, Inc. (AXSM) is $279.25, 98.1% above the recent $140.94. Over the past 90 days analysts logged 0 upgrades, 14 maintains, and 0 downgrades. Here is how the bullish and bearish cases on AXSM line up.
The bullish case
- Wall Street's consensus price target of $279.25 implies +98.1% upside from $140.94.
- The Street's most bullish target is $380.00 (+169.6%).
- Material positive event.
- Strong 5.2% price move.
- Positive price momentum.
The bearish case
- Axsome Therapeutics reported Q3 2026 earnings today, beating revenue estimates but posting a net loss, according to Zacks and the company's earnings release via Globe Newswire.
- Axsome Therapeutics, Inc. moved -3.74% intraday from $203.10 to $195.50.
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 10, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for AXSM
In-depth AXSM event analyses
Frequently asked questions about AXSM
Why did Axsome Therapeutics, Inc. (AXSM) stock move?
AXSM climbed 5.2% to $140.94. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did AXSM stock rise?
AXSM gained 5.21% ($6.98) versus the prior close of $133.96, last trading at $140.94 on 1.1× average volume.
When is Axsome Therapeutics, Inc.'s next earnings date?
AXSM's next earnings report is estimated for 2027-02-22 — about 104 days away.
What is the analyst price target for AXSM?
The consensus analyst price target for AXSM is $279.25, about 98.1% above the current $140.94. Over the past 90 days, analysts recorded 0 upgrades, 14 maintains, and 0 downgrades.
How BestStocks tracks AXSM
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared AXSM-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for AXSM, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 10, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.